Factors Associated With Response to Nivolumab in Renal Cell Carcinoma
A study was conducted to assess factors contributing to response to nivolumab treatment for advanced clear cell renal cell carcinoma.
A study was conducted to assess factors contributing to response to nivolumab treatment for advanced clear cell renal cell carcinoma.
Risk for death lower for patients with lung cancer, renal cell carcinoma, melanoma with versus without obesity
Fotivda is an oral vascular endothelial growth factor tyrosine kinase inhibitor.
Lenvatinib was associated with the most significant probability of producing all grades of cardiovascular injury and hypertension.
Belzutifan is a potent and selective inhibitor of HIF-2α.
The approval was based on data from a phase 3 TIVO-3 study that compared tivozanib to sorafenib in adults with relapsed or refractory advanced RCC after 2 or more prior systemic therapies.
Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC
Progression-free, overall survival significantly longer with combo versus sunitinib for advanced renal cell carcinoma
New study data offer insight on the mechanisms of angiotensin converting enzyme 2 (ACE2) in clear cell renal cell carcinoma (ccRCC).
Investigators of this retrospective observational cohort study evaluated outcomes with cabozantinib or other tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma (RCC) following immune checkpoint inhibition.